Adding Non-Waived Testing Under a Certificate of Waiver
Dr. Alvarez runs a solo family medicine practice in a town of 8,000. The practice has held a CLIA Certificate of Waiver since 2016 and performs only waived rapid strep, urine pregnancy, and fingerstick glucose tests. To improve diabetes care, Dr. Alvarez purchases a chemistry analyzer and plans to begin HbA1c and basic metabolic panel testing on Monday. He has hired a retired medical technologist to work three mornings per week, has a small utility room for the analyzer, and has not submitted any CMS-116 application or notified the state agency. The analyzer vendor told him that because the instruments are "CLIA approved," the practice can start testing and "upgrade the certificate later." Dr. Alvarez asks whether he may begin testing next week and what he must do to make the new testing compliant. The practice has no written QC plan for non-waived testing and has not enrolled in proficiency testing.
1. May Dr. Alvarez begin HbA1c and basic metabolic panel testing next Monday under the existing Certificate of Waiver? Explain the regulatory basis and the risks of starting before authorization.
Read the worked answer
No. A Certificate of Waiver authorizes only waived testing. HbA1c and a basic metabolic panel are non-waived tests, so the practice would need a Certificate of Compliance or Certificate of Accreditation before reporting results.
Reasoning steps:
- Identify the certificate type. The practice holds only a waiver, not a certificate that covers moderate-complexity testing.
- Identify the tests. HbA1c and BMP are not waived; vendor statements that an instrument is "CLIA approved" do not change the test's categorization or the laboratory's certificate obligations.
- Identify the application route. The practice must submit CMS-116, select the appropriate certificate, pay applicable fees, and meet the personnel, QC, PT, and director requirements before testing begins.
- Assess the risk. Starting early is unauthorized testing. Results may be treated as invalid, and the laboratory can face enforcement action, including civil money penalties or loss of its certificate.
- Correct the plan. The start date must be moved until the new certificate is issued and all conditions are in place. The vendor's assurance is not a substitute for the certificate.
2. Assuming Dr. Alvarez wants to add these non-waived tests, identify the minimum steps and conditions the practice must satisfy before reporting patient results.
Read the worked answer
The practice must build the infrastructure for moderate-complexity testing before any patient result is reported:
- Certificate: submit CMS-116, obtain the correct certificate, and pay the fee; do not begin testing until it is effective.
- Director: document that the laboratory director meets the qualifications for moderate-complexity testing.
- Personnel: verify that the hired technologist meets CLIA qualifications for the testing performed and document training on the specific methods.
- Proficiency testing: enroll with an approved PT provider for each specialty, subspecialty, and analyte before patient testing, including HbA1c and the chemistry analytes.
- QC: write and follow a QC program for the analyzer, including control frequency, acceptance limits, corrective action, calibration, and reagent lot verification.
- Procedures: maintain written procedures for specimen handling, test performance, reporting, and corrective action.
- Facility and safety: confirm the utility room is suitable for the analyzer and that safety and infection-control requirements are met.
- Survey: be prepared for an initial survey or accreditation process, depending on the certificate route.
The key judgment is sequencing: authorization, personnel, PT enrollment, and QC must precede reporting, not follow it.
3. Dr. Alvarez is board-certified in family medicine but has no formal laboratory training beyond residency. Can he serve as laboratory director for moderate-complexity testing? What alternatives exist?
Read the worked answer
Possibly, but not automatically. A physician director for moderate-complexity testing must meet the CLIA director qualifications, which generally require documented laboratory training or experience in addition to the medical degree. Board certification in family medicine alone does not establish that qualification.
The practice should:
- Review the director qualification regulation for moderate-complexity testing.
- Document any residency laboratory training or supervised laboratory experience; a bare assertion is not enough.
- If Dr. Alvarez does not qualify, retain a qualified laboratory director, such as a pathologist or another physician with documented laboratory training and experience, who accepts the regulatory responsibilities.
- Alternatively, continue performing only waived tests and do not add HbA1c or BMP.
The director role is not ceremonial. The director is responsible for QC, PT review, personnel, and overall compliance, so assigning an unqualified person creates a condition-level deficiency even if a qualified technologist performs the bench work.